Latest news with #Baral
Yahoo
11-07-2025
- Business
- Yahoo
TD Cowen Remains Bullish on Amicus Therapeutics (FOLD) With a $20 PT
Amicus Therapeutics, Inc. (NASDAQ:FOLD) is one of the 13 Best Healthcare Stocks to Buy Under $10. On May 1, analyst Ritu Baral from TD Cowen maintained a Buy rating on Amicus Therapeutics, Inc. (NASDAQ:FOLD), keeping the price target at $20.00. Doctors in a lab coat attending to a patient receiving enzyme replacement therapies. The analyst based the rating on the company's future growth potential and strategic positioning, stating that Amicus Therapeutics, Inc. (NASDAQ:FOLD) has maintained a positive outlook for GAAP profitability in H2 2025. This trend emerged despite the Q1 revenue misses for both PomOp and Galafold, which were affected by higher UK VPAG rebates. Baral thus reasoned that these trends suggest confidence in the company's operations and its ability to manage costs and drive future profitability. Another factor supporting the analyst's positive rating is Amicus Therapeutics, Inc.'s (NASDAQ:FOLD) pipeline expansion, especially with the in-licensing of DMX-200 for FSGS. This highlights the company's commitment to boosting its long-term growth prospects and expanding its product offerings, according to Baral. Amicus Therapeutics, Inc. (NASDAQ:FOLD) discovers, develops, and delivers medicines to treat metabolic diseases. Its product portfolio includes the first and only approved oral precision medicine to treat Fabry disease, a clinical-stage treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. While we acknowledge the potential of FOLD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.
Business Insider
05-07-2025
- Business
- Business Insider
Analysts Offer Insights on Healthcare Companies: Praxis Precision Medicines (PRAX) and OS Therapies Incorporated (OSTX)
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Praxis Precision Medicines (PRAX – Research Report) and OS Therapies Incorporated (OSTX – Research Report) with bullish sentiments. Don't Miss TipRanks' Half-Year Sale Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. Praxis Precision Medicines (PRAX) In a report issued on July 3, Ritu Baral from TD Cowen maintained a Buy rating on Praxis Precision Medicines, with a price target of $61.00. The company's shares closed last Thursday at $47.26. According to Baral is a 4-star analyst with an average return of 7.9% and a 46.1% success rate. Baral covers the Healthcare sector, focusing on stocks such as Sagimet Biosciences, Inc. Class A, Sionna Therapeutics, Inc., and Milestone Pharmaceuticals. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Praxis Precision Medicines with a $111.13 average price target. OS Therapies Incorporated (OSTX) Lake Street analyst Chad Messer maintained a Buy rating on OS Therapies Incorporated on July 3 and set a price target of $19.00. The company's shares closed last Thursday at $1.83, close to its 52-week low of $1.41. According to Messer has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -2.2% and a 37.5% success rate. Messer covers the Healthcare sector, focusing on stocks such as Bolt Biotherapeutics, Lantern Pharma, and Immunome. Currently, the analyst consensus on OS Therapies Incorporated is a Moderate Buy with an average price target of $12.50, representing a 541.0% upside. In a report issued on July 1, Maxim Group also maintained a Buy rating on the stock with a $6.00 price target.
Axios
29-06-2025
- Business
- Axios
Exclusive: Niural lands $31M to streamline global payroll
Niural, a global payroll and finance operations startup, has raised $31 million in Series A funding, CEO Nami Baral tells Axios exclusively. Why it matters: Over half of all global companies experience payroll-processing errors at least once per quarter, per Deloitte. How it works: Niural operates a full-stack global professional employer organization (PEO) that automates payroll, benefits, vendor payments, and compliance in over 150 countries. The platform is powered by Emma, an AI agent that provides guidance and can also execute payroll and HR actions on behalf of users. Emma, Baral says, "doesn't just surface help‑desk articles; it actually completes the payroll and HR actions for you." With that automation, she says Niural can cut HR costs by up to 50% while saving clients over 60 hours of manual work each month. Between the lines: In addition to payroll, Niural offers services like accounts receivable, accounts payable and cash flow reporting, which reduces the need for managing multiple vendors. Customers initially come to Niural to manage payroll, but Baral says most adopt three to six other tools once they see the platform. "We saw a gap in how companies managed money outflows — payroll, benefits, vendor payments. That's where we start, but we aim to be the system of intelligence for the entire CFO suite," Baral says. By the numbers: Niural claims it has grown ARR 7x in the past year and reduced payroll errors for its customers by 90%. The big picture: The global payroll market is becoming crowded with players like Rippling, Deel, Remote and others expanding internationally. But Baral says most PEOs rely on third-party software to manage large parts of their operations. Niural, by contrast, spent multiple years building its payroll stack from scratch. "Ninety percent of U.S. PEOs still run on the same third-party system — Prism HR. Its infrastructure hasn't changed in decades. We knew we had to own the stack to innovate," she says. Zoom in: Marathon Management Partners led the round, which included participation from M13, Inspired Capital, Newform Capital, and others. Marathon's Gokul Rajaram, a board member at Coinbase, The Trade Desk, and Pinterest, is joining Niural's board as part of the deal. Niural previously raised $10 million in seed funding.
Business Insider
17-06-2025
- Business
- Business Insider
TD Cowen Sticks to Their Hold Rating for SAGE Therapeutics (SAGE)
TD Cowen analyst Ritu Baral maintained a Hold rating on SAGE Therapeutics (SAGE – Research Report) today and set a price target of $8.50. The company's shares closed today at $9.07. Confident Investing Starts Here: Baral covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, Alnylam Pharma, and Neurogene. According to TipRanks, Baral has an average return of 7.3% and a 46.40% success rate on recommended stocks. SAGE Therapeutics has an analyst consensus of Hold, with a price target consensus of $8.75, representing a -3.53% downside. In a report released today, Wedbush also maintained a Hold rating on the stock with a $8.50 price target. Based on SAGE Therapeutics' latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $14.06 million and a GAAP net loss of $62.21 million. In comparison, last year the company earned a revenue of $7.9 million and had a GAAP net loss of $108.48 million
Business Insider
11-06-2025
- Business
- Business Insider
TD Cowen Remains a Hold on Spero Therapeutics (SPRO)
TD Cowen analyst Ritu Baral maintained a Hold rating on Spero Therapeutics (SPRO – Research Report) today. The company's shares closed today at $2.85. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Baral covers the Healthcare sector, focusing on stocks such as Alnylam Pharma, Sarepta Therapeutics, and Vera Therapeutics. According to TipRanks, Baral has an average return of 7.1% and a 47.08% success rate on recommended stocks. The word on The Street in general, suggests a Hold analyst consensus rating for Spero Therapeutics.
